Tag: pharmaceuticals

  • Finance Friday: 4 March 2011

    Here are recent angel and venture finance transactions for science- and engineering-based companies, as reported by Xconomy and Venture Capital Reporter. Biomedical/Life Sciences Retina Implant AG in Reutlingen, Germany, a medical device company developing sub-retinal implants to help visually impaired people improve their sight, secured $18 million in its second round of equity funding from…

  • Online Cancer Genomics Tool for Clinicians Unveiled

    Vanderbilt-Ingram Cancer Center (VICC) in Nashville, Tennessee has launched a cancer decision-support tool to help physicians track the latest developments in personalized cancer medicine and find clinical research trials for their patients. The online service called My Cancer Genome (MyCancerGenome.org) is part of VICC’s Personalized Cancer Medicine Initiative, started last year. The Web-accessible database is…

  • Lycera Corp., Merck to Partner on Autoimmune Drugs

    Lycera Corporation, a biopharmaceutical company in Plymouth, Michigan, says it has a collaboration agreement with the global drug maker company Merck to develop drug candidates that treat major autoimmune diseases such as rheumatoid arthritis, psoriasis, inflammatory bowel disease, and multiple sclerosis. Under the agreement, Lycera can receive up to $307 million, as well as later…

  • Contracts Awarded for New Flu Vaccine Technologies

    The U.S. Department of Health and Human Services (HHS) awarded contracts to two companies to help make flu vaccines available quickly for seasonal outbreaks and pandemics. The contracts total $215 million from HHS’s Biomedical Advanced Research and Development Authority. HHS awarded one contract to Novavax Inc., of Rockville, Maryland, for $97 million over the first…

  • Tufts University Gets Patent for Kidney Disease Treatment

    Researchers at Tufts University’s veterinary school in Grafton, Massachusetts have received a U.S. patent for an antibody-based treatment for hemolytic uremic syndrome (HUS), a potentially fatal outcome of E. coli poisoning and a leading cause of kidney failure in children. The Tufts technology covered by the patent, developed by microbiology professor Saul Tzipori, uses human…

  • Finance Friday: 25 February 2011

    Here are recent angel and venture finance transactions for science- and engineering-based companies, as reported by Xconomy. Biomedical/Life Sciences CardioFocus in Marlborough, Massachusetts. Attrial fibrilliation devices. $13.6 million in equity financing. CalciMedica in San Diego, California. Biotech with experimental psoriasis candidate. $6 million in venture financing. Acetylon Pharmaceuticals, in Boston, Massacusetts. Drugs to treat cancer…

  • Small Business Grant Awarded for Tuberculosis Test

    Chembio Diagnostics Inc. in Medford, New York has received a three-year $2.9 million Small Business Innovative Research (SBIR) grant from the National Institutes of Health (NIH) to continue development of a simple, rapid, inexpensive, and accurate blood serum test for tuberculosis. The grant funds further development of the test, following an earlier SBIR grant to…

  • Pharma Companies Developing 460 Orphan Drugs

    A report from the Pharmaceutical Research and Manufacturers of America (PhRMA) says there are now 460 medicines for rare  or “orphan” diseases in late stages of the pipeline, either in clinical trials or awaiting Food and Drug Administration (FDA) review. The group says this is the largest number of drugs for orphan diseases in development…

  • Canadians, Americans Get Different Drug Info in Web Searches

    A research team at University of British Columbia (UBC) in Vancouver, Canada report that Canadians and Americans get much different search results when they look up prescription drug information online. Their findings were published yesterday in the online issue of the Annals of Pharmacotherapy (paid subscription required). The researchers found residents of the United States…

  • U.S. Patent Issued for Gastrointestinal Therapy

    Synergy Pharmaceuticals Inc. in New York says today the U.S. Patent and Trademark Office awarded a patent to the company for its drug candidate SP-333 to treat various gastrointestinal disorders. U.S. Patent No. 7,879,802 was issued on 1 February, according to the company. The patent claims the composition of SP-333 and use in the treatment…